SG10202007233TA - IMMUNOGLOBULINS BINDING HUMAN Vγ9Vδ2 T CELL RECEPTORS - Google Patents

IMMUNOGLOBULINS BINDING HUMAN Vγ9Vδ2 T CELL RECEPTORS

Info

Publication number: SG10202007233TA
Authority: SG; Singapore
Prior art keywords: cell receptors; binding human; human vγ9vδ2; immunoglobulins binding; immunoglobulins
Prior art date: 2014-04-10

Application number

SG10202007233TA

Inventor

Der Vliet Johannes Jelle Van

Bruin Renée Cornelia Gerarda De

Gruijl Tanja Denise De

Hendrik Marinus Willem Verheul

Original Assignee

Lava Therapeutics B V

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-04-10

Filing date

2015-04-10

Publication date

2020-09-29

2015-04-10 Application filed by Lava Therapeutics B V filed Critical Lava Therapeutics B V

2020-09-29 Publication of SG10202007233TA publication Critical patent/SG10202007233TA/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Cell Biology (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Urology & Nephrology (AREA)
Medicinal Preparation (AREA)
Hematology (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Virology (AREA)
Tropical Medicine & Parasitology (AREA)
Zoology (AREA)
Food Science & Technology (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Investigating Or Analysing Biological Materials (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

SG10202007233TA 2014-04-10 2015-04-10 IMMUNOGLOBULINS BINDING HUMAN Vγ9Vδ2 T CELL RECEPTORS SG10202007233TA (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
NL2012604		2014-04-10

Publications (1)

Publication Number	Publication Date
SG10202007233TA true SG10202007233TA (en)	2020-09-29

Family

ID=50896416

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SG11201609417VA SG11201609417VA (en)	2014-04-10	2015-04-10	IMMUNOGLOBULINS BINDING HUMAN Vγ9Vδ2 T CELL RECEPTORS
SG10202007233TA SG10202007233TA (en)	2014-04-10	2015-04-10	IMMUNOGLOBULINS BINDING HUMAN Vγ9Vδ2 T CELL RECEPTORS

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
SG11201609417VA SG11201609417VA (en)	2014-04-10	2015-04-10	IMMUNOGLOBULINS BINDING HUMAN Vγ9Vδ2 T CELL RECEPTORS

Country Status (10)

Country	Link
US (4)	US10501540B2 (en)
EP (1)	EP3129404A1 (en)
JP (4)	JP6617138B2 (en)
KR (2)	KR102359264B1 (en)
CN (2)	CN106536557B (en)
AU (3)	AU2015244489B2 (en)
EA (2)	EA039086B1 (en)
MX (2)	MX385333B (en)
SG (2)	SG11201609417VA (en)
WO (1)	WO2015156673A1 (en)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK3220926T3 (en) *	2014-11-17	2025-03-24	Adicet Therapeutics Inc	ENGINEERED GAMMA-DELTA T-CELLS
JP6743051B2 (en)	2015-01-27	2020-08-19	ラヴァ・セラピューティクス・ベー・フェー	Single domain antibody targeting CD1D
WO2017197347A1 (en)	2016-05-12	2017-11-16	Adicet Bio, Inc.	METHODS FOR SELECTIVE EXPANSION OF γδ T-CELL POPULATIONS AND COMPOSITIONS THEREOF
US10356636B2 (en) *	2017-04-03	2019-07-16	Qualcomm Incorporated	Techniques and apparatuses to improve drone-mounted user equipment performance
WO2019099744A1 (en)	2017-11-15	2019-05-23	Adicet Bio, Inc.	METHODS FOR SELECTIVE EXPANSION OF δ3 γδ T-CELL POPULATIONS AND COMPOSITIONS THEREOF
CN108659130B (en) *	2018-05-28	2021-09-10	长春力太生物技术有限公司	Anti-carcinoembryonic antigen nano antibody and application thereof
CN112703201A (en) *	2018-07-05	2021-04-23	诺沃班德畜牧业治疗公司	Antibodies against poultry pathogens and uses thereof
US20220111043A1 (en) *	2018-09-19	2022-04-14	Lava Therapeutics B.V.	Dual acting cd1d immunoglobulin
US12410225B2 (en)	2018-11-08	2025-09-09	Orionis Biosciences, Inc	Modulation of dendritic cell lineages
SG11202106895UA (en)	2019-01-07	2021-07-29	Shattuck Labs Inc	Heterodimeric proteins for modulating gamma delta t cells
US11098093B2 (en)	2019-01-07	2021-08-24	Shattuck Labs, Inc.	Heterodimeric proteins for modulating gamma delta T cells
NL2022494B1 (en)	2019-02-01	2020-08-19	Lava Therapeutics B V	Novel CD40-binding antibodies
JP2022519082A (en)	2019-02-01	2022-03-18	ラヴァ・セラピューティクス・ベー・フェー	New CD40 binding antibody
JP7308477B2 (en) *	2019-03-11	2023-07-14	パナソニックＩｐマネジメント株式会社	Antibody, complex, detection device and detection method using the same
JP7686571B2 (en) *	2019-05-08	2025-06-02	ヤンセンバイオテツク，インコーポレーテツド	Materials and methods for modulating T cell-mediated immunity
EP3792283A1 (en)	2019-09-16	2021-03-17	Lava Therapeutics B.V.	Treatment of cancer comprising administration of vgamma9vdelta2 t cell receptor binding antibodies
GB201918279D0 (en) *	2019-12-12	2020-01-29	Vib Vzw	Glycosylated single chain immunoglobulin domains
KR20220147631A (en) *	2020-02-27	2022-11-03	얀센 바이오테크 인코포레이티드	Materials and methods for modulating an immune response
CA3172449A1 (en)	2020-03-27	2021-09-30	Erik Hans MANTING	Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
CN116133679A (en)	2020-06-30	2023-05-16	门德斯有限公司	Use of leukemia derived cells in ovarian cancer vaccines
JP2023532807A (en) *	2020-07-08	2023-07-31	ラヴァ・セラピューティクス・エヌ・ヴイ	Antibodies that bind to PSMA and gamma-delta T cell receptors
AU2021372463A1 (en) *	2020-10-28	2023-06-22	Janssen Biotech, Inc.	Compositions and methods for modulating delta gamma chain mediated immunity
CA3196677A1 (en)	2020-11-05	2022-05-12	Erik Hans MANTING	Use of tumor-independent antigens in immunotherapies
CN116635421A (en) *	2020-11-06	2023-08-22	安进公司	Polypeptide constructs that bind CD3
US20240024475A1 (en) *	2020-12-01	2024-01-25	Cure Genetics Co., Ltd	Antigen-Binding Protein Targeting CD70 and Use Thereof
EP4259660A1 (en)	2020-12-10	2023-10-18	LAVA Therapeutics N.V.	Antibodies that bind gamma-delta t cell receptors
CA3203705A1 (en)	2021-01-22	2022-07-28	Erik Hans MANTING	Methods of tumor vaccination
CA3209454A1 (en)	2021-02-26	2022-09-01	Robertus Cornelis ROOVERS	Antibodies that bind cd123 and gamma-delta t cell receptors
JP2024533457A (en)	2021-09-13	2024-09-12	ヤンセンバイオテツク，インコーポレーテツド	CD33xVδ2 MULTISIGNANCY ANTIBODIES FOR THE TREATMENT OF CANCER
WO2023067138A1 (en)	2021-10-21	2023-04-27	LAVA Therapeutics N.V.	Uses of gamma delta t cell activating antibodies
CN119213028A (en) *	2022-01-05	2024-12-27	印希比生物科学有限公司	Polypeptides binding to γδ T cells and their uses
CN115043936B (en) *	2022-03-31	2023-06-27	深圳市人民医院	Nanometer antibody targeting novel coronavirus and preparation method and application thereof
EP4285926A1 (en)	2022-05-30	2023-12-06	LAVA Therapeutics N.V.	Combination treatment for chronic lymphocytic leukemia
EP4292610A1 (en)	2022-06-15	2023-12-20	LAVA Therapeutics N.V.	Variant antibodies that bind gamma-delta t cell receptors
EP4292609A1 (en)	2022-06-15	2023-12-20	LAVA Therapeutics N.V.	Compositions comprising antibodies that bind gamma-delta t cell receptors
CN116178538B (en) *	2023-01-05	2024-08-02	暨南大学	Nanoantibodies targeting heat shock protein 70 and preparation methods and applications thereof
WO2024173376A2 (en) *	2023-02-13	2024-08-22	LAVA Therapeutics N.V.	Combination therapy comprising multispecific gamma delta tcr antibodies
CN116284405B (en) *	2023-03-15	2024-03-19	中国科学技术大学	Nanometer antibody targeting CD150 protein and application thereof
WO2024200573A1 (en)	2023-03-27	2024-10-03	LAVA Therapeutics N.V.	Nectin-4 binding agents and methods of use
EP4438624A1 (en)	2023-03-27	2024-10-02	LAVA Therapeutics N.V.	Antibodies that bind nectin-4 and gamma-delta t cell receptors
WO2025012118A2 (en)	2023-07-07	2025-01-16	LAVA Therapeutics N.V.	5t4 binding agents and methods of use
TW202535947A (en)	2023-12-08	2025-09-16	美商健生生物科技公司	CD33 ANTIBODIES, CD33/Vδ2 MULTISPECIFIC ANTIBODIES AND USES THEREOF
CN118496370A (en) *	2024-06-07	2024-08-16	南方医科大学深圳医院	Targeted ALOX5 nano antibody and application thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2698880B1 (en) *	1992-11-25	1995-02-24	Inst Nat Sante Rech Med	Process for the production of soluble T receptors, products thus obtained and their use in diagnostic or therapeutic compositions.
EP2390270A1 (en) *	2003-01-10	2011-11-30	Ablynx N.V.	Therapeutic polypeptides, homologues thereof, fragments thereof and for use in modulating platelet-mediated aggregation
EP1627231A2 (en) *	2003-05-23	2006-02-22	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Improvements to gamma delta t cell-mediated therapy
EA010350B1 (en) *	2004-06-03	2008-08-29	Новиммун С.А.	Anti-cd3 antibodies and methods of use thereof
ITRM20070437A1 (en) *	2007-08-10	2009-02-11	Istituto Naz Per Le Malattie I	METHOD FOR THE GENERATION AND EXPANSION OF CELLS T RANGE / DELTA REGULATORY CELLS SOON OBTAINED AND THEIR APPLICATIONS
WO2009131730A2 (en) *	2008-01-31	2009-10-29	University Of Iowa Research Foundation	IMMUNOGENIC COMPOSITIONS FOR ACTIVATING γδ T CELLS
CN102154205A (en) *	2011-01-31	2011-08-17	郑骏年	Method for preparing high-purity and high-cytotoxin-activity gamma delta T cells
EP2807189B1 (en) *	2012-01-23	2019-03-20	Ablynx N.V.	Sequences directed against hepatocyte growth factor (hgf) and polypeptides comprising the same for the treatment of cancers and/or tumors
CN103571791B (en) *	2012-02-10	2015-05-13	深圳市合一康生物科技股份有限公司	Morphology and purity and immunophenotyping detection method of human (gamma)(delta)T cells
PT2831109T (en) *	2012-03-28	2018-02-07	Gadeta B V	SUMMARY

2015
- 2015-04-10 EA EA201692039A patent/EA039086B1/en unknown
- 2015-04-10 AU AU2015244489A patent/AU2015244489B2/en active Active
- 2015-04-10 CN CN201580029256.8A patent/CN106536557B/en active Active
- 2015-04-10 CN CN202110414426.1A patent/CN113105550A/en active Pending
- 2015-04-10 JP JP2017505036A patent/JP6617138B2/en active Active
- 2015-04-10 EP EP15722781.0A patent/EP3129404A1/en active Pending
- 2015-04-10 KR KR1020167031470A patent/KR102359264B1/en active Active
- 2015-04-10 MX MX2016013332A patent/MX385333B/en unknown
- 2015-04-10 WO PCT/NL2015/050235 patent/WO2015156673A1/en not_active Ceased
- 2015-04-10 SG SG11201609417VA patent/SG11201609417VA/en unknown
- 2015-04-10 KR KR1020227003540A patent/KR102601469B1/en active Active
- 2015-04-10 US US15/302,927 patent/US10501540B2/en active Active
- 2015-04-10 EA EA202192165A patent/EA202192165A1/en unknown
- 2015-04-10 SG SG10202007233TA patent/SG10202007233TA/en unknown
2016
- 2016-10-10 MX MX2021009674A patent/MX2021009674A/en unknown
2019
- 2019-05-16 US US16/414,424 patent/US20190263908A1/en not_active Abandoned
- 2019-11-14 JP JP2019206255A patent/JP7094931B2/en active Active
2020
- 2020-08-05 AU AU2020213325A patent/AU2020213325B2/en active Active
2021
- 2021-10-28 US US17/513,621 patent/US11384145B2/en active Active
2022
- 2022-06-22 JP JP2022100477A patent/JP7342202B2/en active Active
- 2022-12-15 US US18/066,791 patent/US20230212290A1/en active Pending
2023
- 2023-06-30 AU AU2023204215A patent/AU2023204215A1/en active Pending
- 2023-08-30 JP JP2023140495A patent/JP7583130B2/en active Active

Also Published As

Publication number	Publication date
EA039086B1 (en)	2021-12-01
JP7583130B2 (en)	2024-11-13
CN106536557A (en)	2017-03-22
JP2017513521A (en)	2017-06-01
JP7342202B2 (en)	2023-09-11
AU2020213325B2 (en)	2023-03-30
US10501540B2 (en)	2019-12-10
AU2015244489B2 (en)	2020-08-27
AU2020213325A1 (en)	2020-08-27
CN113105550A (en)	2021-07-13
KR102359264B1 (en)	2022-02-04
JP7094931B2 (en)	2022-07-04
US20170029506A1 (en)	2017-02-02
WO2015156673A1 (en)	2015-10-15
MX2021009674A (en)	2021-09-08
MX2016013332A (en)	2017-05-01
KR102601469B1 (en)	2023-11-14
KR20170019343A (en)	2017-02-21
KR20220021015A (en)	2022-02-21
JP2023165723A (en)	2023-11-17
US20230212290A1 (en)	2023-07-06
AU2023204215A1 (en)	2023-07-20
AU2015244489A1 (en)	2016-12-01
US20190263908A1 (en)	2019-08-29
MX385333B (en)	2025-03-18
EA202192165A1 (en)	2021-12-31
JP2020029461A (en)	2020-02-27
EP3129404A1 (en)	2017-02-15
JP2022136078A (en)	2022-09-15
JP6617138B2 (en)	2019-12-11
US20220098301A1 (en)	2022-03-31
CN106536557B (en)	2021-05-04
US11384145B2 (en)	2022-07-12
SG11201609417VA (en)	2016-12-29
EA201692039A1 (en)	2017-05-31
CA2948812A1 (en)	2015-10-15

Publication	Publication Date	Title
SG11201609417VA (en)	2016-12-29	IMMUNOGLOBULINS BINDING HUMAN Vγ9Vδ2 T CELL RECEPTORS
ZA201806866B (en)	2021-04-28	T cell receptors
ZA201806862B (en)	2021-04-28	T cell receptors
IL262144A (en)	2018-11-29	T cell receptors
ZA201806865B (en)	2021-04-28	T cell receptors
IL264425B1 (en)	2023-05-01	Anti-kras-g12d t cell receptors
PL4219542T3 (en)	2024-09-16	T cell receptors
ZA201701823B (en)	2019-06-26	T cell receptors
GB201522592D0 (en)	2016-02-03	T cell receptors
SG11201708313QA (en)	2017-11-29	T cell receptor
PT3101132T (en)	2021-12-31	Anti-transthyretin human antibody
PL3180356T3 (en)	2020-04-30	Human anti-fgfr4 antibody
SMT202300448T1 (en)	2024-05-14	T cell receptors
PL2998145T3 (en)	2020-03-31	Canvas cover
GB201518991D0 (en)	2015-12-09	T cell receptors
GB201403306D0 (en)	2014-04-09	Binding Polypeptides
GB201420069D0 (en)	2014-12-24	T cell recognised peptide epitopes